Bronchogen

1. Overview

Bronchogen (also designated T-33) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Leu (AEDL), developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a tissue-specific bioregulator targeting the bronchial epithelium [1][7]. It belongs to the family of Khavinson peptide bioregulators -- short synthetic peptides (2-4 amino acids) proposed to regulate gene expression in their target organs through direct interaction with DNA and histone proteins [4][8].

Bronchogen was designed based on amino acid analysis of polypeptide extracts from bronchial mucosa tissue. The peptide is intended to restore and maintain normal function of bronchial epithelial cells, including mucin production, surfactant protein synthesis, and epithelial differentiation pathways [1]. Unlike conventional pharmaceutical agents that act through receptor-mediated signaling, Khavinson's bioregulator theory proposes that AEDL penetrates cell nuclei and interacts directly with DNA at specific sequence motifs, thereby modulating transcription of tissue-relevant genes [3][4][9].

Published preclinical research demonstrates tissue-specific effects in bronchial epithelial cell cultures and animal models of lung pathology, including COPD, bacterial lung inflammation, and fibrosis [1][6]. However, no human clinical trials meeting international regulatory standards have been published, and essentially all research originates from Khavinson's group and affiliated institutions.

Molecular Weight

~432 g/mol

Chemical Formula

C16H27N3O9 (approximate)

Sequence

Ala-Glu-Asp-Leu (AEDL)

Peptide Type

Synthetic tetrapeptide bioregulator (Khavinson class)

Mechanism

Tissue-specific gene expression regulation in bronchial epithelium via DNA and histone interaction; activates MUC4, MUC5AC, SFTPA1, NKX2-1, and differentiation genes

Routes Studied

Oral (capsules), sublingual, subcutaneous (preclinical)

FDA Status

Not approved; not evaluated by any Western regulatory agency

WADA Status

Not specifically listed; falls under S0 (Non-Approved Substances)

2. Mechanism of Action

Bronchogen operates through the peptide bioregulation mechanism proposed by Khavinson, involving direct nuclear penetration and gene expression modulation in bronchial epithelial cells.

DNA Interaction

Biophysical studies using spectrophotometry, viscometry, and circular dichroism have demonstrated that the AEDL peptide interacts with DNA in the major groove at the guanine N7 site without visible distortion of the double helix structure [1][3]. The peptide binds specifically to a CTCC DNA sequence motif [3]. These findings suggest a mechanism distinct from conventional receptor-mediated signaling, in which AEDL directly accesses chromatin to modulate gene transcription.

Histone Binding

AEDL binds to histone proteins H1, H2b, H3, and H4 at the N-terminal peptide-binding motifs, specifically at the kaakakk sequence -- the same motif targeted by Epithalon (AEDG) [4]. This histone interaction is proposed to increase transcriptional availability of gene promoter zones in bronchial epithelial cells.

Gene Expression Regulation

The most extensively characterized effect of AEDL is the tissue-specific regulation of gene expression in bronchial epithelium. In human bronchial epithelial cell cultures, AEDL activates the expression of [1]:

• Differentiation transcription factors: NKX2-1, FOXA1, FOXA2 -- critical for bronchial epithelial cell identity and differentiation
• Secretory cell markers: SCGB1A1, SCGB3A2 -- Clara cell (club cell) secretory proteins involved in airway defense
• Mucin genes: MUC4, MUC5AC -- mucus glycoproteins essential for airway mucosal barrier function
• Surfactant genes: SFTPA1 -- surfactant protein A, important for innate pulmonary immune defense

Reduced expression of MUC4, MUC5AC, and SFTPA1 correlates with the development of bronchopulmonary pathology, suggesting that AEDL may protect against disease by maintaining their normal expression levels [1].

Epigenetic Modulation

Studies on aging human bronchial epithelial cells demonstrated that AEDL modulates DNA methylation patterns during cellular aging, suggesting an epigenetic mechanism for its tissue-specific effects [2]. This is consistent with the broader Khavinson bioregulator theory, which proposes that short peptides act as epigenetic regulators rather than through conventional receptor signaling [4].

3. Researched Applications

Chronic Obstructive Pulmonary Disease (COPD)

Evidence level: Preclinical (animal models), limited clinical observational data

In a murine COPD model, Bronchogen treatment reduced several hallmark pathological features: goblet cell hyperplasia (excess mucus-producing cells), squamous metaplasia (abnormal epithelial transformation), and emphysematous areas (loss of lung elasticity). The peptide also increased secretory immunoglobulin A (sIgA) levels, suggesting restoration of mucosal immune barrier function [1].

Oral administration of Bronchogen (AEDL) combined with Chonluten (EDG) has been reported effective in the treatment of COPD and chronic bronchitis with asthmatic component as part of combined therapy in Russian clinical settings [5][7]. These clinical observations have not been validated through controlled trials meeting international standards.

Lung Inflammation and Fibrosis

Evidence level: Preclinical

AEDL demonstrated protective effects in animal models of acute bacterial lung inflammation, pulmonary fibrosis, and toxic lung damage [1]. The proposed mechanism involves maintenance of bronchial epithelial differentiation and mucin production during inflammatory stress.

Bronchial Epithelial Regeneration

Evidence level: In vitro

Bronchogen has been shown to engage regenerative capacity in progenitor cells of the bronchial epithelium, including Clara cells (club cells), basal cells, and type 2 alveolar cells. These progenitor populations are essential for maintaining the integrity of the bronchial lining and initiating repair following injury [1].

COVID-19 Related Lung Pathology

Evidence level: Theoretical/Review

In a 2020 review, Khavinson and colleagues discussed Bronchogen and Chonluten as potential therapeutic agents for respiratory pathology associated with viral infections, including COVID-19-related lung damage, based on their bronchial epithelium protective properties [5]. No clinical data specific to COVID-19 treatment with Bronchogen have been published.

4. Clinical Evidence Summary

5. Dosing in Research

The following table summarizes doses used in published research studies. These are not therapeutic recommendations. Bronchogen is not approved for human use in any major regulatory jurisdiction, and the clinical data available comes exclusively from Russian observational reports that have not been independently replicated.

Commonly Referenced Protocols

In the bioregulator community, Bronchogen is typically referenced as an oral capsule supplement taken at 200-400 mcg per day for courses of 10-30 days, repeated 2-3 times annually. This protocol derives from the Russian supplement formulation rather than from controlled dose-finding studies. Some protocols combine Bronchogen with Chonluten (EDG) for complementary bronchial support.

6. Safety and Side Effects

Published Safety Data

Bronchogen has demonstrated no reported adverse effects in published preclinical studies. As a tetrapeptide composed of common L-amino acids (alanine, glutamic acid, aspartic acid, leucine), it is expected to be metabolized by endogenous peptidases into its constituent amino acids.

In animal models and cell culture studies, no cytotoxic, genotoxic, or mutagenic effects have been reported [1][4]. The peptide did not produce visible distortion of DNA double helix structure upon binding [3].

Critical Safety Gaps

Despite commercial availability, formal toxicology data meeting international regulatory standards is absent:

• No formal dose-escalation or maximum tolerated dose studies
• No reproductive or developmental toxicity studies
• No pharmacokinetic studies defining absorption, distribution, metabolism, or elimination
• No drug interaction studies
• No long-term safety data from controlled human studies
• All safety observations derive from Khavinson's research group

7. Comparison with Related Peptides

Bronchogen (AEDL) vs. Chonluten (EDG)

Both peptides target the bronchial epithelium, but through distinct gene expression profiles. Bronchogen (AEDL) is a tetrapeptide that primarily activates differentiation and mucin genes (NKX2-1, MUC4, MUC5AC, SFTPA1), while Chonluten (EDG) is a tripeptide that regulates stress-response genes (c-Fos, HSP70, SOD, COX-2, TNF-alpha). They are often used in combination in Russian clinical practice for complementary effects on bronchial function.

Bronchogen (AEDL) vs. Epithalon (AEDG)

Both are tetrapeptides sharing the first three amino acids (Ala-Glu-Asp) but differing in the fourth position (Leu vs. Gly). Despite this structural similarity, they display markedly different tissue specificity: Bronchogen targets bronchial epithelium while Epithalon targets the pineal gland and telomerase activation. Both bind to the kaakakk histone motif [4], but their divergent tissue effects are attributed to differences in DNA sequence selectivity.

Bronchogen vs. Conventional Bronchodilators

Unlike beta-2 agonists, anticholinergics, or corticosteroids used in COPD management, Bronchogen does not act through conventional receptor-mediated pharmacology. Its proposed mechanism involves gene expression regulation rather than acute symptom relief. No comparative studies between Bronchogen and standard-of-care therapies have been published.

8. Limitations and Transparency

Several significant limitations apply to the Bronchogen evidence base:

• All published research originates from Khavinson's institute and affiliated laboratories in Russia
• No independent replication by Western research groups has been published
• The molecular mechanism (direct peptide-DNA binding for gene regulation) has not gained acceptance in mainstream molecular biology
• Clinical observations in COPD patients are observational and uncontrolled
• No peer-reviewed, randomized, controlled clinical trials have been conducted
• Commercial availability vastly exceeds scientific validation

9. Pharmacokinetics

No formal pharmacokinetic studies have been published for Bronchogen (AEDL). As a tetrapeptide composed of common L-amino acids, its pharmacokinetic behavior is governed by the general principles of ultrashort peptide metabolism, which present fundamental challenges for oral bioavailability.

Tetrapeptides are substrates for multiple proteolytic enzymes in the gastrointestinal tract, plasma, and tissues. Gastric acid, pancreatic proteases (trypsin, chymotrypsin), and brush border peptidases in the small intestine would be expected to rapidly degrade AEDL before significant absorption occurs. Plasma half-lives for unprotected tetrapeptides are typically measured in seconds to low minutes [8][12]. No studies have measured intact AEDL concentrations in plasma or target tissues following oral administration.

The Khavinson group has proposed that ultrashort peptides may be transported intact across intestinal epithelium via proton-coupled oligopeptide transporters (PepT1/SLC15A1), which accept di- and tripeptides as substrates [9]. However, PepT1's substrate specificity for tetrapeptides is poor, and no direct evidence of intact AEDL transport via this mechanism has been published. The alternative hypothesis -- that AEDL's biological effects are mediated by its degradation products (smaller peptides or free amino acids acting in specific ratios) -- has not been investigated.

The route from intestinal absorption to bronchial epithelium (the proposed target tissue) would require systemic distribution via the bloodstream, adding another pharmacokinetic barrier. Whether orally administered AEDL reaches bronchial cells at biologically active concentrations remains entirely uncharacterized.

10. Dose-Response

No formal dose-response studies have been published for Bronchogen in any species or experimental system. The available dosing data span several orders of magnitude across different experimental contexts without establishing a systematic relationship between dose and effect.

In vitro cell culture studies used concentrations ranging from 10 to the minus 7 to 10 to the minus 12 M [1][6], with gene expression effects (MUC4, MUC5AC, NKX2-1 activation) observed across this range. The biophysical DNA interaction studies demonstrated AEDL binding to the CTCC motif using spectrophotometric methods, but the minimum effective concentration for gene regulatory effects in living cells was not rigorously defined [3].

The standard oral dosing protocol (200-400 mcg per day for 10-30 days) derives from the general Khavinson bioregulator framework rather than from dose-finding studies specific to AEDL [7][8]. No studies have compared different oral doses of Bronchogen for clinical or biochemical endpoints. The animal model studies used 0.1-1 mcg per animal subcutaneously, but scaling these doses to human oral administration involves multiple unvalidated assumptions about bioavailability, species-specific metabolism, and route conversion factors.

11. Comparative Effectiveness

Bronchogen (AEDL) vs. Chonluten (EDG)

Both target bronchial epithelium but through distinct pathways. Bronchogen activates differentiation genes (NKX2-1, MUC4, MUC5AC, SFTPA1) while Chonluten regulates stress-response genes (c-Fos, HSP70, SOD, COX-2, TNF-alpha) [1]. No head-to-head comparative studies have been published. The two are used in combination in Russian clinical practice, with the rationale that Bronchogen restores epithelial identity while Chonluten provides anti-inflammatory and antioxidant protection. The combination protocol in COPD patients lacks controlled trial validation.

Bronchogen vs. Epithalon (AEDG)

Despite sharing three of four amino acids (Ala-Glu-Asp), Bronchogen (AEDL) and Epithalon (AEDG) display markedly different claimed tissue specificities. Epithalon has a substantially larger evidence base, including primate studies, telomerase activation data, and limited human clinical data. Both bind the same kaakakk histone motif [4], yet their divergent effects raise questions about the resolution of tissue specificity achievable through a single amino acid change.

Bronchogen vs. Standard Pulmonary Therapies

No comparative studies exist between Bronchogen and any approved respiratory medication (beta-2 agonists, inhaled corticosteroids, anticholinergics, or PDE4 inhibitors). Standard COPD therapies have decades of RCT evidence, established dose-response relationships, and defined pharmacokinetic profiles. Bronchogen's proposed gene-regulatory mechanism operates on a fundamentally different timescale and through different pathways than conventional bronchodilators or anti-inflammatories.

12. Enhanced Safety

Bronchogen's safety profile rests on the general observation that no adverse effects have been reported in preclinical studies and clinical observations [1][4][7]. As a tetrapeptide of common dietary amino acids (alanine, glutamic acid, aspartic acid, leucine), it is expected to be metabolized into its constituents by endogenous peptidases, with no accumulation or novel metabolites.

The DNA interaction studies showed that AEDL binds DNA in the major groove at N7 guanine without visible distortion of the double helix [3], suggesting that the peptide does not cause structural DNA damage. No genotoxic, mutagenic, or cytotoxic effects have been reported in any published study [1][4].

However, the safety evidence has critical limitations. All safety observations come from Khavinson's group, with no independent safety assessment. No formal toxicology studies (acute, subchronic, chronic, reproductive, or carcinogenicity) meeting ICH or OECD regulatory standards have been conducted. No drug interaction studies have been performed -- this is particularly relevant for patients taking inhaled corticosteroids, bronchodilators, or immunosuppressants for respiratory conditions.

The theoretical safety profile is favorable for a short peptide of natural amino acids, but the absence of systematic safety data means that rare adverse effects, delayed toxicity, or interactions with co-administered medications cannot be excluded. The modulation of mucin gene expression (MUC4, MUC5AC) raises the theoretical concern of excessive mucus production in patients with already hypersecretory conditions, though this has not been observed.

13. Related Peptides

See also: Chonluten, Epithalon, Thymalin

14. References

1. [1] Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. DOI PubMed
2. [2] Ashapkin VV, Kutueva LI, Vanyushin BF, Khavinson VKh. (2015). Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Moscow). DOI PubMed
3. [3] Morozova EA, Khavinson VKh, Linkova NS. (2017). In vitro interaction of the AEDL peptide with DNA. Journal of Structural Chemistry. DOI
4. [4] Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
5. [5] Khavinson VKh, Linkova NS, Kvetnoy IM. (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed
6. [6] Khavinson VKh, Linkova NS, Trofimova SV. (2016). Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine. PubMed
7. [7] Khavinson VKh. (2002). Peptides and ageing. Neuro Endocrinology Letters. PubMed
8. [8] Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
9. [9] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
10. [10] Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. PubMed
11. [11] Khavinson VKh. (2020). Peptide medicines: past, present, future. Klin Med (Mosk).
12. [12] Khavinson VKh, Anisimov VN. (2000). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
13. [13] Ilina A, Khavinson V, Linkova N, Petukhov M. (2022). Neuroepigenetic mechanisms of action of ultrashort peptides in Alzheimer's disease. International Journal of Molecular Sciences. DOI PubMed
14. [14] Khavinson VKh, Linkova NS, Dyatlova AS, Kuznik BI, Umnov RS. (2021). The use of Thymalin for immunocorrection and molecular aspects of biological activity. Biology Bulletin Reviews. DOI PubMed
15. [15] Kuznik BI, Linkova NS, Khavinson VKh. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. International Journal of Molecular Sciences. DOI PubMed